Browsing Tag
Ocugen
5 posts
How the GARDian3 trial could define the next commercial frontier in ophthalmic gene therapy
Discover how Ocugen, Inc.’s GARDian3 trial could redefine the commercial future of ophthalmic gene therapy and what investors should watch next.
Can Ocugen, Inc. disrupt chronic eye injections with a single gene therapy procedure? (NASDAQ: OCGN)
Ocugen, Inc. reports Phase 2 gene therapy results that could reshape retinal treatment economics. Discover what this means for investors and competitors.
Positive early Phase 2 data strengthen Ocugen’s case for OCU410 in the fast-evolving dry AMD treatment market
Find out how Ocugen’s early Phase 2 data for OCU410 could reshape competition and investor sentiment in the fast-growing dry AMD treatment market.
Ocugen reports promising interim results for OCU410 clinical trial in geographic atrophy
Ocugen, Inc. has taken a significant step forward in the fight against geographic atrophy (GA) secondary to dry…
Ocugen secures FDA clearance to begin OCU400 gene therapy trial: What this means for patients with retinitis pigmentosa
Find out how Ocugen’s FDA-approved OCU400 trial is shaping the future of gene therapy for retinitis pigmentosa. Read the full story today.